Eli Lilly & Co.

Stock Exchange: XNYS • Ticker: LLY • HQ: Indianapolis, IN, US • Employees: 41,275

Ranking by technical area
Ranking by strategic pillar

Performance

Eli Lilly remains 17th. The governance of its approach to access has significantly improved: its new Going Beyond Medicines Alone strategy combines its several initiatives on access. It has improved substantially in Market Influence & Compliance, with a more transparent approach to ethical marketing and lobbying, and a broad, risk-based approach to auditing. It uses equitable pricing strategies for one more product than in 2014, and now has three donation programmes. However, it has the smallest pipeline relevant to the Index. It has fallen back in pro-access IP management. During the period of analysis, it was judged to have breached competition law in Mexico. Eli Lilly shows innovation in capacity building but does not clearly demonstrate that all its capacity building activities consistently target local needs.

Change since 2014

Improves its access strategy, including the development of an innovative business model for diabetes in China.

Has the smallest relevant pipeline of all 20 companies measured.

Expanded its intellectual-property-sharing partnership with the Medicines for Malaria Venture in 2015.

Has not yet set targets for registering products for specific diseases or in countries in scope.

Has not yet disclosed price or volume-of-sales information to demonstrate the implementation of its equitable pricing strategies.

Still does not provide pricing guidelines to sales agents or monitor prices or mark ups.

Still does not publish the status of its patents in countries in scope.

Has no publicly available position on the Doha Declaration on TRIPS and public health.

Performs less well in building capacity in manufacturing, offset by an innovative approach to building capacity outside the pharmaceutical value chain.

Continues to engage in donation programmes for diabetes and mental health conditions.

Opportunities

Expand and strengthen its access focus. Eli Lilly currently focuses its access initiatives around products for diabetes and TB. It can go beyond these by drawing upon its diverse expertise in different disease areas and product types. Plus, given that non-communicable diseases (NCDs) are a growing concern in low- and middle-income countries, Eli Lilly can strengthen its approach to affordability here.

Mitigate mark-ups in low- and middle-income countries. Where legally possible, Eli Lilly can provide pricing guidance to sales agents and establish processes for monitoring mark-ups.

Consider local needs and access during product development. Eli Lilly can ensure more of its R&D activities fill key product gaps by drawing on its experience in understanding local product development needs, gathered, e.g., through the Lilly China Research and Development Centre. As new products move into late stages of development, Eli Lilly can make plans for products to reach poor and vulnerable populations in low- and middle-income countries.

Strengthen and expand capacity building efforts. Eli Lilly can draw on its experience in building capacity outside the value chain and from its multi-drug-resistant TB (MDR-TB) partnership, to strengthen and expand its activities within the value chain. For example, it can expand its efforts to build manufacturing capacity, working with local partners to identify shared goals. Set registration targets for key diseases. Eli Lilly can set targets for registering products in countries in scope. This helps to ensure early access to products in high-need countries. The company can also register existing products in more countries with high burdens of disease.

Consider access barriers for animal health products. Given the large numbers of people in low- and middle-income countries living with livestock and other animals, Eli Lilly can leverage its acquisition of Novartis’ Animal Health business to improve human health by addressing zoonotic diseases.

Sales and operations

Eli Lilly is divided into two segments: Human Pharmaceutical Products and Animal Health Products. Its portfolio is focused on oncology, neuroscience, men’s health, immunology, endocrinology and cardiovascular disease. With the acquisition of Novartis’ Animal Health business, Eli Lilly became the world’s second largest animal health company.

The company has sales in 72 countries in scope, and approximately 15% of its revenues derive from emerging and frontier markets.

Sales in countries in scope
Sales by division
Sales by region

Portfolio and pipeline

Eli Lilly has the smallest pipeline of projects, with one R&D project that addresses the needs of people in countries in scope. With 14 medicines, its portfolio is also one of the smallest of the companies in scope. Eli Lilly’s portfolio includes medicines targeting ischaemic heart disease, diabetes and mental health conditions. In 2014, Eli Lilly gained market approval from the FDA for dulaglutide (Trulicity®) for the treatment of type 2 diabetes. In addition to products for NCDs, Eli Lilly’s portfolio also contains medicines for infectious diseases: vancomycin, cefaclor and capreomycin.

Products per disease category

Eli Lilly’s portfolio is focused on NCDs: 10 out of the 14 products in its relevant portfolio target one or more NCDs.

Eli Lilly’s relevant R&D project aims to develop a VEGFR1 antibody to target diabetic nephropathy. This product candidate has moved from discovery stage, through preclinical development, and into phase I since 2014. Eli Lilly is not targeting high-priority product gaps with low commercial incentive for diseases in scope.

Pipeline projects

Eli Lilly is not collaborating with external organisations on R&D for diseases in scope.

First-line treatments and essential medicines

Eli Lilly has eight medicines listed on the WHO EML and/or as first-line treatments: olanzapine, glucagon, insulin lispro, vancomycin, capreomycin, quinidine duloxetine and fluoxetine.

Pipeline by stage of development
– Innovative medicines and vaccines

Eli Lilly’s only relevant pipeline project is a new chemical entity (NCE): a VEGFR1 antibody targeting diabetic nephropathy.

Pipeline by stage of development
– Adaptive medicines and vaccines

Eli Lilly is not currently adapting any products to meet the needs of people living in low- or middle-income countries.

Please refer to the pdf of the report card (that can be downloaded here) for information on Eli Lilly’s performance per technical area.

Sign up to receive updates about our work.